In Friday's Analysts' Actions, Wall Street firms are giving positive remarks on Yelp (YELP) and Medtronic (MDT) while another firm isn't too happy about GameStop (GME). RBC Capital Markets gave Yelp a boost to OUTPERFORM from SECTOR PERFORM with a $42 price target. Analysts said 'We continue to see unique core and strategic value' in the company. Yelp is a leader they add, in helping to connect small businesses to consumers and, its app rankings have gone up. Given these reasons, analysts are bullish. In another note, Goldman Sachs added Medtronic to 'Americas Conviction BUY List' and lifted its price target to $90 from $87. Here's why: improving end-markets, new product launches and financial flexibility. Overall, analysts said it has the strongest fundamentals the company has seen in nearly a decade. The firm added that investors shouldn't overlook these strengths. Meanwhile, analysts are not too optimistic on GameStop. KeyBanc Capital Markets dropped its rating to SECTOR WEIGHT from OVERWEIGHT. The firm sees some risks as physical software sales have been struggling to grow. On top of this, it appears that the company has 'very little profitability in digital.' TheStreet's U-Jin Lee reports in New York.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.